Biogen Inc. Common Stock (BIIB) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and con...
Biogen Inc. Common Stock's revenue increased 2.2% year over year, from $9.68B to $9.89B.
Net income decreased 20.8% over the same period, from $1.63B to $1.29B.
Over the 9-year period from FY2016 to FY2025, revenue declined by 14% in total.
Total debt decreased by 100.0% to $0.
The debt-to-equity ratio stands at 0.00, indicating a conservative leverage profile.
Operating cash flow declined 23.3% to $2.20B.
Biogen Inc. Common Stock maintains a healthy net profit margin of 13.1%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $2.47B+0.0% | $388.5M | $1.83B | $451.0M | $935.6M | $28.31B | $4.55B | $16.36B |
| Q4 FY2024 | $2.45B-0.5% | $266.7M | $1.87B | $999.5M | $760.9M | $28.05B | $1.75B | $16.72B |
| Q1 FY2025 | $2.43B-1.0% | $240.5M | $1.80B | $676.6M | $259.3M | $28.03B | $4.55B | $16.98B |
| Q2 FY2025 | $2.65B+8.8% | $634.8M | $2.04B | $378.6M | $160.9M | $28.33B | $6.28B | $17.63B |
| Q3 FY2025 | $2.53B-4.2% | $466.5M | $1.86B | $557.3M | $1.27B | $29.21B | $6.29B | $18.21B |
| Q4 FY2025 | $2.28B-10.1% | $-48.9M | $1.78B | $-56.0M | $511.9M | $29.44B | $0 | $18.26B |
| Q1 FY2026 | $2.48B+8.7% | $319.5M | $1.82B | $377.7M | $645.5M | N/A | N/A | N/A |
| Q2 FY2026 | $2.74B+10.4% | $97.5M | $1.96B | $875.3M | $448.9M | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Biogen Inc. Common Stock (BIIB) Financial Statements & Revenue History
Biogen Inc. Common Stock (BIIB) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry trading at $232.65 with a market capitalization of $34. This page provides 42 historical financial statements for Biogen Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Biogen Inc. Common Stock reported revenue of $9.9 billion, representing 2.2% year-over-year growth. The net profit margin of 13.1% indicates moderate profitability. The debt-to-equity ratio of 0.00 shows conservative leverage.
BIIB Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Biogen Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BIIB is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BIIB's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Biogen Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BIIB's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BIIB Financial Data
Investors use Biogen Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BIIB's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BIIB's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BIIB's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Biogen Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BIIB trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.